Login / Signup

Clinical response beyond the Systemic Lupus Erythematosus Responder Index: post-hoc analysis of the BLISS-SC study.

Ronald F Van VollenhovenWilliam StohlRichard A FurieNorma Lynn FoxJames G GroarkDamon BassMilena KurtineczBonnie F PobinerWilliam J EastmanTania Gonzalez-RiveraDavid Gordon
Published in: Lupus science & medicine (2018)
SRI response is associated with improvements in clinical and laboratory measures, strengthening its value as a clinically meaningful primary endpoint in clinical trials.
Keyphrases
  • systemic lupus erythematosus
  • clinical trial
  • rheumatoid arthritis
  • disease activity
  • phase ii